Selumetinib is currently FDA approved for children 2 years and older with symptomatic and inoperable plexiform neurofibromas.

They form on the protective cover around your nerves. That’s called the sheath. Most plexiform neurofibromas (PNs) are benign, or non-cancerous. Some -- about 8% to 15% -- do turn into cancer.

DataM Intelligence | competitive Intelligence NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibito ...

ERIN DUNBAR: Plural neurofibromas are the signature abnormal tumor growth found in neurofibromatosis type 1, which is a heritable or familial or genetic condition, and plexiform neurofibromas are ...

If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for ...

Neurofibromatosis 1-associated plexiform neurofibromas (NF1-PN) are benign tumors that develop along peripheral nerves throughout the body. They are typically present at birth or develop in early ...

Panelists discuss how MEK inhibitors, such as trametinib and selumetinib, are emerging as first-line treatments for symptomatic NF1-associated plexiform neurofibromas, especially in progressive or ...

EMA committee recommends marketing approval for SpringWorks’ mirdametinib to treat adult & paediatric patients with NF1-PN: Stamford, Connecticut Tuesday, May 27, 2025, 12:00 Hr ...

Exploratory objectives include assessing the effects of PAS-004 on cutaneous neurofibromas. The first active clinical trial site is the Royal North Shore Hospital in Sydney, Australia, which is ...

The FDA approved Gomekli for patients aged 2 years and older diagnosed with neurofibromatosis type 1 and symptomatic plexiform neurofibromas not amenable to complete resection. Image: Adobe Stock ...

The trial aims to provide insights on both plexiform and cutaneous neurofibromas and is supported by an anticipated Australian R&D Tax Incentive refund of up to 48.5% of eligible costs.